Nephrology Articles & Analysis: Older
33 news found
“It is clear that a cost effective, rapid technology that can sequence long fragments of DNA, such as those provided by Oxford Nanopore and a robust interpretation solution such as SeqOne are necessary to extract the full potential of third generation sequencing technology in nephrology and aHUS” said Pr. Laurent Mesnard, the PI heading the study. ...
Going forward, we will leverage our advantages in nephrology and hematology and more areas to make the medicines accessible to patients and benefiting more Chinese ...
The approval of Kerendia in China is based on the results of the pivotal Phase III study FIDELIO-DKD, presented at the American Society of Nephrology’s (ASN) Kidney Week 2020 and simultaneously published in the New England Journal of Medicine in October 2020. ...
ByBayer AG
Before that, she served as Vice President, Sales for Amgen Inc., where she successfully led the Hospital and Nephrology sales teams. In addition, she served as Senior Vice President, Specialty Biotherapeutics and Managed Care for Genentech, Inc. ...
A post-hoc analysis of pooled data from the similarly designed 48-week AURA-LV and 52-week AURORA 1 studies were presented in an oral session at the EULAR 2022 European Congress of Rheumatology by Hans-Joachim Anders, M.D., Professor of Nephrology at the University of Munich (LMU). The pooled analysis from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies assessed the efficacy of ...
(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France. These data show that INV-202, the company’s lead peripheral CB1 blocker, ...
Onno Teng, M.D., Ph.D., President of the National Foundation of the Autoimmune Research & Collaboration Hubs (ARCH) Date: Friday, May 20, 2022 Time: 17:00-18:30 CEST Title: “Early Reductions in Proteinuria with Voclosporin Treatment across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials” Presenting author: Anca Askanase, M.D., M.P.H., Columbia ...
It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. ...
The FIDELIO-DKD study was presented at the American Society of Nephrology’s (ASN) Kidney Week 2020; the FIGARO-DKD study was presented at ESC Congress 2021. ...
ByBayer AG
It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. ...
” The approval of Kerendia in the EU is based on the results of the pivotal Phase III FIDELIO-DKD study, presented at the American Society of Nephrology’s (ASN) Kidney Week 2020 and simultaneously published in the New England Journal of Medicine (NEJM) in October 2020. ...
ByBayer AG
Glenn Chertow, Chief of the Division of Nephrology at Stanford University School of Medicine, who serves as Chairman of CloudCath’s Clinical Advisory Board. ...
Versius has been introduced at both Ain Shams University Specialized Hospital and the International Hospital for Urology & Nephrology (IHUN), as CMR works with ATG group to meet significant demand for Versius from one of the largest countries in the Middle East and Africa (MEA) region. ...
SIUT is a renowned, charitable institute, providing free state of the art medical treatment to all patients, regardless of background or wealth, facilitating the treatment of renal ailments, urological and nephrological conditions, oncological treatments, treatments of hepatic and gastrointestinal diseases, and organ transplantation. ...
Moll, MD, PhD, professor emeritus of vascular surgery at the University Medical Center Utrecht in The Netherlands, provided insights on the progress of the aXess trial in an interview with Healio Nephrology. For more on Xeltis’ aXess, the first restorative synthetic hemodialysis access graft, on the unmet research needs that the aXess trial is aiming to address and on ...
” The positive CHMP opinion is based on the results of the pivotal Phase III FIDELIO-DKD study, presented at the American Society of Nephrology’s (ASN) Kidney Week 2020 and simultaneously published in the New England Journal of Medicine (NEJM) in October 2020. ...
ByBayer AG
Franz Schaefer, Professor of Pediatrics and Chief of the Pediatric Nephrology Division at Heidelberg University Hospital. “If successful, insights from this study could be of great significance to children living with chronic kidney disease and their ...
ByBayer AG
Data from the analyses were presented at the American Society of Nephrology (ASN)’s Kidney Week 2021 in two oral presentations and two late-breaking posters. ...
ByBayer AG
(Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced results of the PHYOX™2 pivotal clinical trial of nedosiran, an investigational GalXC™ RNAi candidate for the treatment of primary hyperoxaluria (PH), in a late-breaker poster presentation at the American Society of Nephrology (ASN) Kidney Week ...
The data will be presented as an oral abstract by Aimee Payne, M.D., Ph.D., Professor of Dermatology at the University of Pennsylvania’s Perelman School of Medicine and co-chair of the Scientific Advisory Board and co-founder at Cabaletta Bio at the American Society of Nephrology (ASN) Kidney Week 2021 being held virtually from November 4-7, 2021. ...